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Abstract Article Info 
Introduction: Treatment results for nasopharyngeal carcinoma (NPC) have been improved, but there were still 
some patients who developed localized persistent or local recurrent. Local recurrence still represents a major 
cause of mortality and morbidity also management still challenging issues. 
Case Report: A 27-year-old woman presented with bilateral conductive hearing loss, dysphagia, rhinorrhoea, 
epistaxis, and cranial nerve palsy after chemo radiation for NPC. The results of nasopharyngoscopy, CT scan, 
and PET scan were not found a mass in the nasopharynx. The result of nasopharyngeal biopsy result was 
undifferentiated carcinoma. Patient diagnosed with recurrent NPC and planned for re-radiotherapy. 
Conclusion: After complete treatment for NPC we must immediately ensure recurrence and choose the next 
appropriate treatment. 
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1. CASE REPORT 
Treatment result for nasopharyngeal carcinoma (NPC) have improved due to 
the advances in imaging, radiotherapy techniques, and the use of combined 
treatment with chemotherapy. However there are patients who developed localized 
persistent or recurrent carcinoma after completion of combined therapy. Local 
recurrence still represents a major cause of mortality and morbidity in advanced 
stages and management of local failure remains a challenging issue in NPC. 
A 27-year-old female patient, a midwife, came to ENT outpatient ward at Ulin 
hospital on November 18th 2018 with chief complaint otorrhoea from the left ear 
for 6 months, which was getting worse. The discharge can be runny or thick, but no 
smell. Bilateral hearing loss and tinnitus for 5 years, more severe on the left ear. 
She has been feeling stuck and tastes a lot of phlegm in the throat every day 
when waking up in the morning for 3 months but improved after drinking. There 
was a bilateral rhinorrhoea for 9 years, the discharge was runny nose until thick 
snot. The patient got epistaxis 4 days ago and there was a history of epistaxis 9 
years ago. Often sneezing for 4 years. No complaint of a lump in the neck. 
History of double vision 5 years ago. There was head feeling heavy for 5 years, 
especially when looking down. 
She has been diagnosed as NPC 5 years ago (August 22nd 2013) according to 
nasopharyngeal biopsy result was undifferentiated carcinoma nasopharynx (picture 
1). The patient has been received radiotherapy 25 times at Ulin Hospital 
Banjarmasin and 13 times at Cipto Mangunkusumo Hospital Jakarta. 
Chemotherapy was given 6 times, 3 times each at Cipto Mangunkusumo Hospital 
Jakarta and Ulin Hospital Banjarmasin performed by a hemato-oncology specialist. 
Picture 1. The nasopharynx biopsy result at August 22nd 2013 
Head CT scan result after chemoradiation on February 2nd, 2014 was 
normal nasopharynx space and abdominal USG on February 10th, 2014 
there were no abnormalities. Whole-body PET scan August 28th, 2014 there 
was no mass at the nasopharynx, radioopaque at the left ethmoidal and 
sphenoidal sinus, no lymphadenopathy with FDG catch in the mediastinum, 
hilus, and bilateral axilla. Audiometry at February 13th 2014, the result was 
bilateral conductive hearing loss There was a history of often eat salted fish, 
but no history of smoking and drink alcoholic beverages. There was no 
family history has a malignant tumor. 
On August 8th, 2017 she has been diagnosed bilateral effusion otitis 
media. The patient underwent a bilateral ventilating tube insertion and 
nasopharyngeal biopsy under general anesthesia on August 16th, 2017. The 
result of nasopharyngeal biopsy (August 26th 2017) was undifferentiated 
carcinoma (WHO type 3) (Picture 2). 
 
Picture 2. The nasopharynx biopsy result at August 26th 2017 
On physical examination we obtained good general condition, 
awareness was conscious, vital sign within normal limit. There was no 
anemia/jaundice/dyspnoea/cyanosis. The patient can be delivered well. 
On the right ear there was no discharge and intact tympanic membrane, 
but retraction, no conus of light. On the left ear there was serous discharge, 
central perforation at the tympanic membrane. From anterior rhinoscopy, 
there was no discharge, normal size/color of the concha, no mass, and palate 







molle phenomenon positive on both sides. On the throat there was a 
deviation of the tongue and negative gag reflex. There was no neck mass. 
Hematology laboratory result obtained Haemoglobin 10,7 g/dl, 
Leukocyte count 4,8x103, trombocyte 353x103 , Haemotocrit 33%, Ureum 
9 mg/dl and Creatinin 0,7 mg/dl.  
Nasopharyngoscopy on November 17th, 2018 there was thick and 
purulent discharge, some were attached dry secretion, clear like glass. There 
was not look like a mass on the Rossenmuller fossa, roof, and wall of the 
nasopharynx, although some were difficult to evaluate because they were 
closed secretion (Picture 3). 
                            
Picture 3. Nasopharyngoscopy does not appear mass, just thick secretion 
Currently a diagnosis was made as recurrent NPC with the differential 
diagnosis was persistent NPC and bilateral serous otitis media. On the head 
and neck CT scan on November 22nd 2018 we obtained a conclusion as 
NPC residual in the ethmoid sinus, not very contrasting, differential 
diagnosis of fibrosis (Picture 4 & 5). 
. 
Picture 4. The nasopharyng does not appear mass 
 
Picture 5. The right ethmoidal sinus is radiopaque 
2. DISCUSSION 
Nasopharyngeal carcinoma (NPC) is a rare malignancy in most of the 
world but common in Southern China. The incidence and mortality in China 
and the constituents area are 3.16 and 1.53 per 100,000 people, respectively, 
according to the national population in 2010. The world age-standardized 
incidence and mortality were 2.44 and 1.18 per 100,000 people, respectively 
[1]. Overall incidence NPC in Indonesia 5.66/100,000, equaling roughly 
1000 new cases per month, reflected a major health problem in Indonesia 
particularly because most of these patients were referred to the hospital a 
late-stage [2]. 
Different factors are thought to contribute to the pathogenesis of cases 
in endemic and non–endemic regions. Epstein-Barr virus (EBV) infection, 
environmental factors, and genetic predisposition are proposed to be the 
main contributing factors in endemic regions, while the classic risk factors 
for other head and neck tumors such as smoking, alcohol and human 
papillomavirus (HPV) infection are thought to account more for cases in 
non-endemic areas [3]. 
Recurrent NPC is defined as tumor relapse after the achievement of 
complete remission with radical chemotherapy. Recurrent NPC can further 
be subdivided into local and regional recurrence [4]. Local recurrence of 
NPC become less common since the use of intensity-modulated 
radiotherapy and chemotherapy [5]. Despite significant improvements in 
local control due to advances in radiotherapy, local recurrence, and residual 
disease remain the main reasons for failure in patients with advances 
nasopharyngeal carcinoma. Local alone and regional alone failures 
respectively account for 70% and 25% of rnpc cases, and 8%-28% of patient 
experience synchronous locoregional failure [4]. The outcome for patients 
with recurrent or metastatic NPC is very poor, with median overall survival 
(OS) about 20 months [6]. 
Domestic and foreign studies have indicated that the clinical features of 
recurrent NPC may be different from primary NPC. The incidence of 
recurrent NPC was higher in men than in women. The male to female ratio 
was about 2.5 to 1 in some report and the patient median age is 46 years. 
The mainly pathologic type of newly diagnosed patients in regions with high 
incidence was WHO III. The usual condition was the patients with tumor 
over deep submucosa, basilar skull, or an intracranial area adjacent to the 
critical structures that might have technical difficulty or high morbidity 
probability for biopsy [5]. 
After the first course of radiotherapy, patients often present with fibrous 
hyperplasia of the nasopharynx and poor local circulation due to local 
vascular occlusion. This condition can lead to low efficacy of the treatment 
and many side effects from re-irradiation alone. Also, the residual tumor 
after the first treatment may acquire mutation or some mechanism that are 
likely to persist and render the tumor resistant to the treatment [7]. 
In this case there was a woman 27 years old after 38 times radiotherapy 
and 6 times chemotherapy. Evaluation with head and neck CT scan even 
whole-body PET scan there was no mass on the nasopharynx space, but 
there were still complaints of hearing loss with bilateral conduction hearing 
loss audiometry result. Besides that patients also complain of dysphagia, 
rhinorrhoea, and epistaxis.  







NPC cancer cells can easily disseminate locally in many ways into 
the nearby critical structure. Thus, the local spread of the tumor is 
usually observed as direct extension anteriorly to the nasal cavity and 
orbit; superiorly and posteriorly to the base of the skull, sphenoid sinus, 
and clivus; inferiorly to the oropharynx and/or laterally into the lateral 
parapharyngeal spaces. The Eustachian tube is located beside the 
nasopharynx and it connects the lateral wall of the nasopharynx to the 
middle ear [8]. 
NPC most commonly as a cervical lymph node enlargement; the tumor 
may not be clinically apparent at the time of presentation. Other presenting 
features of NPC include a bloody nasal discharge, or less frequently, cranial 
nerve palsies. Patient with NPC may also have otologic symptoms, 
including deafness due to the middle ear effusion, and conductive or 
sensorineural hearing loss after radiotherapy [9]. 
Early detection of persistent or recurrent disease is of paramount 
importance. For patients with elevated anti-EBV titers or suspicious 
endoscopic examination, a biopsy of the nasopharynx is then indicated to 
detect the recurrence in its early stages. CT scan delineates the extent of the 
tumor in the nasopharynx and whether it has affected the surrounding bony 
structure. MRI, aside from providing better images of soft tissue, also shows 
tumor size and extension to the skull base and intracranial cavity. The 
detection of the cervical lymph node metastases on presentation has 
improved with MRI and positron emission tomography (PET) and can be 
cytologically confirmed through fine needle aspiration cytology [10]. 
The majority of recurrences occurred within the first five years. Thus, 
if patient have no recurrence within five years, they are much less likely to 
have a recurrence at all. The prognosis after relapse varied with nodal status, 
stage of the first diagnosis as well as the remission duration after treatment. 
Local recurrences had a better prognosis than distant recurrences, while 
distant metastases to the bone had a similar prognosis with those to liver and 
multi-organ involvement [11]. 
In this case patient were not examined for nasopharyngeal biopsy 
immediately after chemoradiation. Nasopharyngeal biopsy was only 
performed when the procedure for grommet insertion after the diagnosis 
serous otitis media was confirmed.There was no difference in 
histopathological type between before chemotherapy and 3 years after 
chemotherapy. 
With improvements in radiotherapy and the continous intensive 
awareness of comprehensive treatment, the 5-year overall survival rate is 
between 59.0% and 761%. However, local and regional recurrence is still 
the main treatment failure of NPC, and the 5-year cumulative rate of 
nasopharynx and cervical lymph node recurrence is 15.0-22.0% [12]. 
Treatment of local failure is challenging, due to anatomical difficult 
accessibility of the nasopharynx and high risk on therapy related 
complication. Treatment option include surgery, reirradiation by external 
beam, brachytherapy or stereotactic radiotherapy, photodynamic therapy 
and chemotherapy. For early stage residual disease (rT1-2), a significant 
benefit is found when salvage treatment is performed. Radiation and 
surgical modalitites have comparable response, survival and complication 
rates. For more advanced tumors (rT3-4), the benevit salvage treatment is 
less clear, probably due to the high treatment related morbidity and 
mortality, caused by large tumor volumes and involvement of surrounding 
structures [13]. An accepted approach in the management of recurrent NPC 
is the delivery of as second round of radiotherapy for patients not eligible 
for nasopharyngectomy. Reradiotherapy is an effective and safe salvage 
treatment strategy for recurrent NPC [14]. 
In this case from the last head and neck CT scan result there are still 
doubt from the radiologist. Although the are not too different from the 
previous examination. It makes us difficult to make correct decision of 
treatment or other examination. But after planning for nasopharyngeal 
biopsy we must decide choice treatment to that patient. 
Despite the varying success of surgery or reirradiation in salvage 
therapy or highly selected patients with local recurrence, a vast majority of 
case recurrent disease are only amenable for palliative chemotherapy [15]. 
Recurrent NPC represent a substantial public health issue in the endemic 
areas of Asia. Despite technological improvements in the management of 
this disease entity in primary setting, the likelihood of local recurrent is 
significantly high [16]. 
 
3. CONCLUSION 
One case of recurrent nasopharyngeal carcinoma has been reported, 
manisfesting as bilateral conductive hearing loss, dysphagia, rhinoroe, 
epistaxis and cranial nerve palsy. Nasopharyngoscopy, CT and PET scan 
there was no mass. Biopsy result was undifferentiated carcinoma 
nasopharynx. Early detection of persistent or recurrent disease is paramount 
importance. Treatment of local failure is challenging, due to anatomical 
difficult accessibility of the nasopharynx and high risk on therapy related 
complication. So we must immediately ensure recurrence and choose the 
next appropriate treatment for that case. 
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